Patients with #HeartFailure showed increased myocardial fibroblast activation using [68Ga]FAPI-46 PET/MRI, with distinct patterns by cardiomyopathy etiology, highlighting activated fibroblasts as a potential therapeutic target. ja.ma/4e9mnzy
Among #Medicare beneficiaries, women undergoing #TAVI experienced higher periprocedural complications and mortality but modestly better long-term survival vs men, with their proportion among TAVI recipients declining over time. ja.ma/444KxoM
Diagnosis of #TransthyretinCardiacAmyloidosis was frequently delayed >6 months after #HeartFailure in Medicare beneficiaries, especially among women and those with aortic stenosis, coronary artery disease, diabetes, or hypertension. ja.ma/4gisDpV
A novel provocation test clinically diagnosed #CalciumReleaseDeficiencySyndrome in a family with unexplained sudden cardiac arrest and death, with pause-dependent T-wave changes supporting CRDS risk stratification.
ja.ma/4ovJzLz
Among #Medicare beneficiaries, women undergoing #TAVI experienced higher periprocedural complications and mortality but modestly better long-term survival vs men, with their proportion among TAVI recipients declining over time. ja.ma/3S80WpN
💬 Editorial: MK-7 supplementation modestly slowed #CoronaryArteryCalcification progression, but evidence is insufficient regarding clinical benefits or impact on cardiovascular events.
ja.ma/4oollTM
Among US veterans with #HeartFailure with reduced ejection fraction, fewer than one-quarter achieved quadruple guideline-directed medical therapy within 2.9 years, and medication copays were associated with lower rates of therapy achievement. ja.ma/3Qk1Tuv
Quadruple guideline-directed medical therapy in #HeartFailure with reduced ejection fraction was projected to offset hospitalization costs by nearly $10 000 per patient-year, frequently yielding net health care savings.
ja.ma/43AkK7P
Editorial: Among patients with #HFrEF in the Veterans Health Administration, fewer than 1 in 6 achieved quadruple therapy and the median time to initiation exceeded 6 months. ja.ma/4fNMr4q
Supplementation with #Menaquinone7 for 2 years modestly slowed progression of #CoronaryArteryCalcification in patients with coronary artery disease, with no major adverse effects.
ja.ma/4uuIy7Z
